Navigation Links
Boston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent
Date:11/11/2011

NATICK, Mass. and SAN FRANCISCO, Nov. 11, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports results from the EVOLVE First Human Use trial demonstrating the non-inferiority of the SYNERGY™ Everolimus-Eluting Stent System compared to the PROMUS Element™ Everolimus-Eluting Stent System in treating de novo coronary artery lesions.  The trial provided 30-day clinical and six-month angiographic primary endpoint data evaluating the safety and effectiveness of the bioabsorbable polymer-coated SYNERGY Stent.  Results were presented today during a late-breaking clinical session by Professor Ian T. Meredith, M.B.B.S., Ph.D., Director of MonashHeart, Monash Medical Centre, Melbourne, Australia, and Principal Investigator of the trial, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

The prospective, randomized, single-blind, non-inferiority trial enrolled 291 patients at 29 sites in Europe, Australia and New Zealand.  Patients were randomized to either one of two dose formulations of everolimus used on the SYNERGY Stent, which employs an ultra-thin abluminal bioabsorbable polymer, or to the commercially available PROMUS Element Stent, which employs the everolimus drug and a permanent durable polymer.  One formulation of the SYNERGY Stent used an everolimus dose and release profile similar to the PROMUS Element Stent, while the second formulation of the SYNERGY Stent used a similar release profile but half the dose of everolimus.

"The SYNERGY Stent met the primary non-inferiority endpoint of six-month late loss compared to the PROMUS Element Stent, demonstrating effectiveness of drug elution from this abluminal bioabsorbable polymer," said Dr. Meredith.  "The platform also appears to be safe with very low rates of myocardial infarc
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
(Date:5/19/2013)... 20, 2013 Claret Medical, Inc. announced the publication ... Mieghem et al., Histopathology of Embolic Debris ... print in Circulation, May 7 th this research is ... Rotterdam, the Netherlands and the pathology team ... Cardiovascular Pathology Institute, Gaithersburg, Maryland.  This is ...
(Date:5/18/2013)... , May 18, 2013 Faruqi & ... is investigating potential securities fraud at AVEO Pharmaceuticals, ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... its executives violated federal securities laws by issuing ... Phase III drug trials for Tivopath (tivozanib) (titled ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR 2Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... N.J., May 14, 2012  MAQUET Cardiovascular LLC, a leading ... received 510(k) clearance from the U.S. Food and Drug ... 40cc intra-aortic balloon (IAB) catheters. These new, larger volume ... hemodynamic support, regardless of their height.  ...
... The increasing incidence of thrombosis, paralleled by ... motivating the need for novel alternatives. Establishing end-user ... market advancement. However, the launch of three blockbuster ... therapeutics market address these challenges. It is also ...
Cached Medicine Technology:MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes 2MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes 3European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan 2European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan 3
(Date:5/20/2013)... 20, 2013 Sporturf, an international manufacturer ... its presence in the Midwest with the opening of ... Missouri. Sporturf Midwest is under the leadership of ... Missouri and Kansas. , “This strategic move ... been in before,” noted Shonk. “Bringing an ISO manufacturer ...
(Date:5/20/2013)... Online education provides the convenience, ... does not offer. According to the American Heart ... switching classroom learning to eLearning due to changing ... helped maximize training budgets, but it is also ... by 25–60%. A higher retention of content is ...
(Date:5/20/2013)... limb is lost as a consequence of diabetic foot ... that can change this situation are very limited. In ... School and the Department of Medical Biochemistry and Biophysics ... wound treatment that may completely change the lives of ... severe type of chronic wounds that largely impair the ...
(Date:5/20/2013)... 2013 BenefitMall, the leading ... payroll products and services and CompuPay, Inc., ... as finalists for the 2013 American Business Awards. BenefitMall ... Year category, and CompuPay is a finalist for Customer ... be a Gold, Silver or Bronze Stevie® Award Winner ...
(Date:5/20/2013)... 2013 Soliant Health, a leading specialty healthcare ... voting for its fifth annual Most Beautiful Hospitals in the ... year, Soliant decided to bypass its routine selection process and ... received to be in the running for the 2013 Most ... May 20 and runs through June 23. Winners will be ...
Breaking Medicine News(10 mins):Health News:Sporturf Expands into the Midwestern U.S. 2Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 2Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 3Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 4Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 5Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 6Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 7Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 8Health News:Vote for Soliant Health's 2013 Most Beautiful Hospitals in the U.S. 9
... In a research study appearing in the journal ... Harbor Laboratory (CSHL) and four other institutions have identified a ... has limited treatment options and one of the worst one-year ... that up to 15% of liver tumors are "driven" by ...
... Mutations in three pathways important for suppressing tumors ... that strikes children and adults. But new research ... those changes alone are not sufficient to cause ... different points in the same disrupted regulatory pathways. ...
... Spanish . The Hospital Clnic of Barcelona presented today ... Felipe Garcia and Dr. Agata Len , from the Hospital ... Gatell . The tool has been created by a team from the ... and Csar Cceres . Through a direct connection via a webcam, ...
... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
... the brain transmits messages to other parts of the ... dementia, multiple sclerosis and stroke. Scientists at the ... maintaining the health and function of the segment of ... brain. The study, published in the journal ...
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Stony ... a "wearable," portable PET scanner they,ve developed for rats. ... simultaneously studying brain function and behavior in fully awake, ... validation studies in the April 2011 issue of Nature ...
Cached Medicine News:Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3Health News:Key mutations act cooperatively to fuel aggressive brain tumor 2Health News:Key mutations act cooperatively to fuel aggressive brain tumor 3Health News:Virtual assistance is confirmed as an effective tool in monitoring HIV patients 2Health News:Virtual assistance is confirmed as an effective tool in monitoring HIV patients 3Health News:Miniature 'wearable' PET scanner ready for use 2Health News:Miniature 'wearable' PET scanner ready for use 3Health News:Miniature 'wearable' PET scanner ready for use 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: